相关实验视频
Updated: May 10, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
可溶性PD-L1:从免疫逃避到癌症治疗
Denisa Dragu1, Laura Georgiana Necula1,2, Coralia Bleotu1
1Stefan S. Nicolau Institute of Virology, 030304 Bucharest, Romania.
溶性PD-L1 (sPD-L1) 在癌症免疫逃避和进展中起着关键作用. 了解sPD-L1机制对于提高免疫疗法在癌症治疗中的有效性至关重要.
科学领域:
- 癌症免疫学 癌症免疫学
- 瘤微环境是一个微环境.
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫疗法为癌症治疗提供了希望,但对有限的患者子集有好处.
- 了解免疫反应和瘤进展因素对于提高治疗结果至关重要.
- 可溶性PD-L1 (sPD-L1) 与免疫调节和癌症生物学有关.
研究的目的:
- 探索sPD-L1生产的起源和机制.
- 阐明sPD-L1在免疫逃避和瘤进展中的作用.
- 评估sPD-L1在恶性瘤中的临床意义.
主要方法:
- 关于sPD-L1.1. 的文献综述
- 对将sPD-L1与疾病严重程度,存活率和治疗反应联系起来的研究进行分析.
- 考虑涉及sPD-L1.1的组合准策略.
主要成果:
- 升高的sPD-L1水平与疾病严重程度和各种癌症的生存率较差有关.
- 在某些恶性瘤中,sPD-L1与治疗反应有关.
- 建议针对sPD-L1的组合疗法的潜力.
结论:
- sPD-L1是癌症免疫逃避和进展的重要因素.
- 需要进一步的研究才能充分理解sPD-L1的动态和免疫抑制机制.
- 向sPD-L1可能会提高当前免疫疗法的疗效.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
相关概念视频
Tumor Immunotherapy
Cell-surface Signaling
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...